CAMBRIDGE, Mass., Nov. 7 The one-day November 8 MASSOpportunities Investor Conference (MASS Opps) features 32 presentations byinnovative private and public biotechnology companies marked for growth in2008. The event showcases six distinguished panels that will cover timely"future of science" themes, insights into biotechnology financing, and stateand federal policy challenges in the coming year. Three keynote addressesround out the exciting and informative program.
Following last year's MASS Opps, presenting companies announced $198million in new venture capital fundraising. Two companies announced IPOstotaling more than $107 million, and twelve alliances/partnerships were formedincluding a $1 billion licensing deal.
The ninth annual MASS Opps, New England's largest biotechnology investorforum, is a robust experience that brings together over 500 CEO's, portfoliomanagers, venture capitalists, healthcare analysts, and professionals from theacademic, clinical, and technology transfer communities who support emergingand developing biotechnology companies.
PRESENTING COMPANIES: PRIVATE
Acceleron Pharma, Aphios Corporation, BIND Biosciences, BioVex, DynogenPharmaceuticals, Ensemble Discovery Corporation, Epitome Biosystems,Genstruct, Gwathmey, Inotek Pharmaceuticals, Logical Therapeutics, MolecularBiometrics, Primera Biosystems, Targeted Cell Therapies, TransMolecular
PRESENTING COMPANIES: PUBLIC
Alnylam Pharmaceuticals, Alseres Pharmaceuticals, ArQule, CombinatorRx,Dyax Corp, EXACT Sciences Corp., Helicos Biosciences Corporation, InfinityPharmaceuticals, Momenta Pharmaceuticals, NitroMed, Oscient PharmaceuticalsCorporation, Pro-Pharmaceuticals, SolMap Pharmaceuticals, SyntaPharmaceuticals, Targanta Therapeutics, Vertex Pharmaceuticals, ZIOPHARMOncology
The Massachusetts Biotechnology Council (MBC) is the nation's oldestbiotechnology trade association. Founded in 1985, the MBC is a not-for-profitorganization that represents and provides services and support for theMassachusetts biotechnology industry. The MBC is committed to advancing thedevelopment of critical new science, technology and medicines that benefitpeople worldwide. Representing over 500 biotechnology companies, academicinstitutions, research hospitals, and service organizations involved in lifesciences and health care, the MBC works to advance policy and promoteeducation, while providing member programs and events, industry information,and services.INDUSTRY PANELS * New Wrinkles on Neurodegenerative Disease * Tools are Back: New Technologies Driving Innovation * The Coming Wave in Nano-Biotechnology * Deal Making and M&A Exits * Funding Early Stage Technology: Corporate Symbiosis, Incubators and New Venture Approaches * A Year of Living Dangerously - Why an Onslaught of New Federal Legislation Presents Biotechnology Its Greatest Challenge Ever KEYNOTE SESSIONS Opening Plenary: Opportunities on the Horizon Moderator: Jeffrey M. Wiesen, Partner & Chairman, Biotechnology Practice, Mintz Levin Keynote Lunch: The Role of Innovation in Biotechnology Dr. Stelios Papadopoulos, Noted former investment banker and biotechnology company builder Closing Plenary: The $1-$3 billion Biotech Funding Puzzle: Putting the Pieces Together Moderator: Glen Giovannetti, Global Biotechnology Leader, Ernst & Young Biotechnology Center
SOURCE Massachusetts Biotechnology Council